ATPO is a novel, potent, selective and competitive antagonist of GluR1-4 (AMPA-preferring) receptors.

IDRA-21 is a positive allosteric modulator (PAM) of the AMPA receptor and a benzothiadiazine derivative.

SDZ 220-581 hydrochloride (SDZ220581; SDZ-220581) is a novel and competitive antagonist of NMDA glutamate receptor subtype (pKi= 7.7) with the potential to be used for Parkinson’s disease.

LY-404187 is an ampakine, AMPA receptor potentiator.

DQP-1105 (DQP1105) is a novel, potent, non-competitive and negative allosteric modulator of the GluN2C/D NMDA receptor with potential to be used for Neuroscience applications.

Sepimostat exhibits neuroprotective activity via NR2B N-methyl-D-aspartate receptor antagonism at the Ifenprodil-binding site of the NR2B subunit.

Farampator (also known as CX-691 or Org24448) is a positive and allosteric modulator of the AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoazolepropionic acid) receptor.

CIQ is a novel, potent and GluN2C/GluN2D subunit-selective NMDA receptor potentiator, which reverses MK-801-induced impairment in prepulse inhibition and working memory in Y-maze test in mice.

Sunifiram (also known as DM-235), a piperazine derived ampakine-like drug, has potent nootropic effects in animal studies with significantly higher potency than piracetam.

Cyclothiazide (CTZ; Fluidil; Doburil; Renazide) is a benzothiadiazide (thiazide) diuretic and antihypertensive approved in the United States in 1963.